



**Lukas Bubendorf**

**Kontakt**

Lukas Bubendorf

## Publikationen (26)

Vlajnic T, Muller D, Ruiz C, Schönegger R, Seifert H, Thalmann G, Zellweger T, Le Magnen C, Rentsch C, Bubendorf L. Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer. *Cancer Rep (Hoboken)* 2023;e1953.

Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aepli S, Mach N, Strelbel R, Hadachik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrusch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. *J Clin Oncol* 2023; 41:5131-5139.

König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. *ESMO Open* 2023; 8:101595.

Gallon J, Rodriguez-Calero A, Benjak A, Akhounova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Feng F, Gillessen S, Chiang C, Rubin M, Piscuoglio S. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. *Cancer Res* 2023; 83:1203-1213.

Rodriguez-Calero A, Gallon J, Akhounova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins S, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Ng C, Gillessen S, Piscuoglio S, Rubin M. Alterations in homologous recombination repair genes in prostate cancer brain metastases. *Nat Commun* 2022; 13:2400.

Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strelbel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. *Eur Urol Oncol* 2022; 5:195-202.

Fuchs J, Früh M, Papachristofilou A, Bubendorf L, Häuptle P, Jost L, Zippelius A, Rothschild S. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study. *PloS one* 2021; 16:e0253601.

Hench I, Vlajnic T, Bubendorf L, Burg P, Tolnay M, Ruiz C, Rothermundt C, Püschel H, Mestre R, Mingrone W, Kremer E, Hermanns T, Hench J, Gillessen Sommer S, Fischer N, Costa L, Cathomas R, Sakk S. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). *Cancers (Basel)* 2019; 11

Savic S, Soltermann A, Zweifel R, Zettl A, von Gunten M, Singer G, Rössle M, Jasarevic Z, Letovanec I, McKee T, Komminoth P, Jochum W, Fleischmann A, Diebold J, Cathomas G, Eppenberger-Castori S, Berezowska S, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. *Virchows Arch* 2019; 475:67-76.

Diebold M, Kohler M, Oezkan F, Darwiche K, Berezowska S, Theegarten D, Grobholz R, Jochum W, Komminoth P, Bubendorf L, Haile S, Hottinger S, Soltermann A, Franzen D. Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study. *Respir Res* 2017; 18:210.

Savic S, Kerr K, Bisig B, Tornillo L, Grieshaber S, Baschiera B, Jochum W, Zimmermann A, Diebold J, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. *Lung Cancer* 2015; 89:104-9.

Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. *Clin Lung Cancer* 2015; 16:358-65.

Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. *PloS one* 2013; 8:e72966.

Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2013; 19:973-80.

Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. *Lung Cancer* 2012; 79:59-64.

Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clin Cancer Res* 2012; 18:6049-57.

Tapia C, Glatz K, Obermann E, Grilli B, Barascud A, Herzog M, Schönenegg R, Savic S, Bubendorf L. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. *Cancer Cytopathol* 2011; 119:404-10.

Savic S, Herman J, Clark D, Zlobec I, Schönenegg R, Spieler P, Loosli H, Bode B, Herzog M, Barascud A, Grilli B, Franco N, Bubendorf L. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. *Chest* 2010; 138:137-44.

Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. *American journal of respiratory and critical care medicine* 2010; 181:181-8.

Zlobec I, Raineri I, Schneider S, Schönenegg R, Grilli B, Herzog M, Savic S, Bubendorf L. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. *Lung cancer (Amsterdam, Netherlands)* 2009

Savic S, Casella R, Zellweger T, Forster T, Sulser T, Gasser T, Schönenegg R, Spieler P, Dalquen P, Eichenberger T, Mattarelli G, Lehmann K, Schmauss M, Engeler D, Thalmann G, Zlobec I, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. *International journal of cancer. Journal international du cancer* 2009; 124:2899-904.

Reichenberger F, Kleiber B, Baschiera B, Bubendorf L, Brutsche M, Dalquen P, Tamm M. Bronchoalveolar lavage quality influences the T4/T8 ratio in sarcoidosis. *Respiratory medicine* 2007; 101:2025-30.

Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski H, Heberer M, Spagnoli G. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007; 120:337-43.

Tapia C, Feichter G, Terracciano L, Cathomas G, Zlobec I, Barascud A, Herzog M, Grilli B, Novotny H, Schönegg R, Wagner U, Savic S, Bubendorf L. HER2 gene status in primary breast cancers and matched distant metastases. Breast cancer research : BCR 2007; 9:R31.

Zellweger T, Benz G, Cathomas G, Mihatsch M, Sulser T, Gasser T, Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119:1660-5.

Bihl M, Tamm M, Gilman J, Goulet S, Yang J, Staedtler F, Eryüksel E, Kehren J, Baty F, Rutherford R, Bubendorf L, Laule-Kilian K, Brutsche M. Progressive pulmonary sarcoidosis--a fibroproliferative process potentially triggered by EGR-1 and IL-6. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders 2006; 23:38-50.

## Projekte (1)

**Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)**

*Grundlagenforschung - 01.04.2012 - 01.09.2013*

*Abgeschlossen*

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)